产品详情
文献和实验
相关推荐
Elaxim™
Tenectase®
Vintor®
Xgrast®300
PEGEX®
Emgrast®-M
Hamsyl®
Gennova Biopharmaceuticals Ltd. 总部位于印度浦那，是一家生物技术公司，致力于开发、生产和商业化生物疗法，以应对各种适应症的威胁生命的疾病。
Gennova 正在通过为制造和成功商业化心血管、神经病学、肾脏病学和肿瘤学领域的生物治疗药物创建高效和有效的解决方案来改变医疗保健。 结合重组 DNA 技术和创新的生物制造实践 该公司使用基于细菌、酵母和哺乳动物的表达平台制造重组产品，并在基于灌注的连续制造技术方面积累了深厚的专业知识。 迄今为止，Gennova 已将七种产品商业化； 5 种生物仿制药，一种仿制药，一种开创性——“世界首创”产品。
Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to developing, producing, and commercializing biotherapeutics to address life-threatening diseases across various indications.
Gennova is transforming healthcare by creating efficient and effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology, and oncology segments. Incorporating recombinant DNA technologies and innovative bio-manufacturing practices The company manufactures its recombinant products using bacterial, yeast, and mammalian-based expression platforms and has developed deep expertise in perfusion-based continuous manufacturing technologies. To date, Gennova has commercialized seven products; 5 biosimilars, one generic, and one pioneering – ‘first in the world’ product.
Tenectase®
Vintor®
Xgrast®300
PEGEX®
Emgrast®-M
Hamsyl®
Gennova Biopharmaceuticals Ltd. 总部位于印度浦那，是一家生物技术公司，致力于开发、生产和商业化生物疗法，以应对各种适应症的威胁生命的疾病。
Gennova 正在通过为制造和成功商业化心血管、神经病学、肾脏病学和肿瘤学领域的生物治疗药物创建高效和有效的解决方案来改变医疗保健。 结合重组 DNA 技术和创新的生物制造实践 该公司使用基于细菌、酵母和哺乳动物的表达平台制造重组产品，并在基于灌注的连续制造技术方面积累了深厚的专业知识。 迄今为止，Gennova 已将七种产品商业化； 5 种生物仿制药，一种仿制药，一种开创性——“世界首创”产品。
Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to developing, producing, and commercializing biotherapeutics to address life-threatening diseases across various indications.
Gennova is transforming healthcare by creating efficient and effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology, and oncology segments. Incorporating recombinant DNA technologies and innovative bio-manufacturing practices The company manufactures its recombinant products using bacterial, yeast, and mammalian-based expression platforms and has developed deep expertise in perfusion-based continuous manufacturing technologies. To date, Gennova has commercialized seven products; 5 biosimilars, one generic, and one pioneering – ‘first in the world’ product.
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
